Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment

被引:65
作者
de Leon, MJ
Segal, S
Tarshish, CY
DeSanti, S
Zinkowski, R
Mehta, PD
Convit, A
Caraos, C
Rusinek, H
Tsui, W
Saint Louis, LA
DeBernardis, J
Kerkman, D
Qadri, F
Gary, A
Lesbre, P
Wisniewski, T
Poirier, J
Davies, P
机构
[1] NYU, Sch Med, Dept Psychiat, Ctr Brain Hlth, New York, NY 10016 USA
[2] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[3] Mol Geriatr Corp, Vernon Hills, IL USA
[4] New York State Off Mental Retardat & Dev Disabil, Inst Basic Res, Staten Isl, NY USA
[5] McGill Univ, Douglas Hosp, Montreal, PQ, Canada
[6] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
cerebrospinal fluid; Alzheimer disease; mild cognitive impairment; magnetic resonance imaging; tau; amyloid beta; longitudinal;
D O I
10.1016/S0304-3940(02)01038-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cross-sectional cerebrospinal fluid (CSF) levels of tau and amyloid (A) beta (beta) are of diagnostic importance for Alzheimer's disease (AD) and mild cognitive impairment (MCI). However, most longitudinal studies of tau fail to demonstrate progression. Because predominantly brain-derived proteins such as tau, have higher ventricle to lumbar ratios, we hypothesized that adjusting for the ventricular enlargement of AD would correct for the dilution of tau, and improve detection of longitudinal change. Abeta which is not exclusively brain derived, shows a ratio <1, and no benefit was expected from adjustment. In a 1 year longitudinal study of eight MCI and ten controls, we examined CSF levels of hyperphosphorylated (P) tau231, Aβ40, and Aβ42. In cross-section, MCI patients showed elevated Ptau231 and Aβ40 levels, and greater ventricular volumes. Longitudinally, only after adjusting for the ventricular volume and only for Ptau231, were increases seen in MCI. Further studies are warranted on mechanisms of tau clearance and on using imaging to interpret CSF studies. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:183 / 186
页数:4
相关论文
共 19 条
[1]   Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].
Andreasen, N ;
Minthon, L ;
Clarberg, A ;
Davidsson, P ;
Gottfries, J ;
Vanmechelen, E ;
Vanderstichele, H ;
Winblad, B ;
Blennow, K .
NEUROLOGY, 1999, 53 (07) :1488-1494
[2]   CSF phosphorylated tau protein and mild cognitive impairment: a prospective study [J].
Arai, H ;
Ishiguro, K ;
Ohno, H ;
Moriyama, M ;
Itoh, N ;
Okamura, N ;
Matsui, T ;
Morikawa, Y ;
Horikawa, E ;
Kohno, H ;
Sasaki, H ;
Imahori, K .
EXPERIMENTAL NEUROLOGY, 2000, 166 (01) :201-203
[3]   Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease [J].
Arai, H ;
Terajima, M ;
Miura, M ;
Higuchi, S ;
Muramatsu, T ;
Matsushita, S ;
Machida, N ;
Nakagawa, T ;
Lee, VMY ;
Trojanowski, JQ ;
Sasaki, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (10) :1228-1231
[4]   Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up [J].
Blomberg, M ;
Jensen, M ;
Basun, H ;
Lannfelt, L ;
Wahlund, LO .
NEUROSCIENCE LETTERS, 1996, 214 (2-3) :163-166
[5]   CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Blennow, K ;
Arai, H ;
Engel, R ;
Hofmann-Kiefer, K ;
McCulloch, C ;
Ptok, U ;
Heun, R ;
Andreasen, N ;
DeBernardis, J ;
Kerkman, D ;
Moeller, HJ ;
Davies, P ;
Hampel, H .
NEUROLOGY, 2002, 59 (04) :627-629
[6]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[7]   Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer's disease [J].
Fox, NC ;
Freeborough, PA .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 1997, 7 (06) :1069-1075
[8]   Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 [J].
Hampel, H ;
Buerger, K ;
Kohnken, R ;
Teipel, SJ ;
Zinkowski, R ;
Moeller, HJ ;
Rapoport, SI ;
Davies, P .
ANNALS OF NEUROLOGY, 2001, 49 (04) :545-546
[9]   Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease [J].
Kanai, M ;
Shizuka, M ;
Urakami, K ;
Matsubara, E ;
Harigaya, Y ;
Okamoto, K ;
Shoji, M .
NEUROSCIENCE LETTERS, 1999, 267 (01) :65-68
[10]   Neuropsychological prediction of decline to dementia in nondemented elderly [J].
Kluger, A ;
Ferris, SH ;
Golomb, J ;
Mittelman, MS ;
Reisberg, B .
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 1999, 12 (04) :168-179